Validation of the Spanish Activity Questionnaire in COPD (SAQ-COPD) in Patients with Chronic Obstructive Pulmonary Disease

Int J Chron Obstruct Pulmon Dis. 2022 Nov 5:17:2835-2846. doi: 10.2147/COPD.S381427. eCollection 2022.

Abstract

Purpose: The Spanish Activity Questionnaire in COPD (SAQ-COPD) is a short, simple physical activity (PA) measurement instrument for patients with chronic obstructive pulmonary disease (COPD). In this study, we analyzed its validity and sensitivity to change.

Methods: Prospective scale validation study. An accelerometer (DynaPort MoveMonitor®) and the Yale Physical Activity Survey (YPAS) were used as reference standards. The analyses examined the criterion validity (Spearman correlations), internal consistency (Cronbach's alpha), factorial structure, test-retest reliability (intraclass correlation coefficient, ICC), sensitivity to change and receiver operating characteristic (ROC) curve to classify patients with low PA.

Results: A total of 300 patients diagnosed with COPD were analyzed (73% males, mean age 66 ± 8 years, 40.3% with severe airflow limitation). Cronbach's alpha was 0.60 and Spearman's correlations with accelerometer measurements of PA [number of steps, metabolic equivalents (MET), physical activity level (PAL)] and YPAS ranged from 0.37 to 0.53 (all p < 0.001). ICC was 0.69 (95% CI 0.61-0.74) and the area under the ROC curve to identify low PA was 0.65 (95% confidence interval: 0.58-0.73). Significant variations in SAQ-COPD scores were found between groups defined by YPAS for change.

Conclusion: The SAQ-COPD questionnaire is a valid instrument for classifying PA in patients with COPD. Correlations with other instruments provide criterion validity and also demonstrate good sensitivity to change.

Keywords: SAQ-COPD; chronic obstructive pulmonary disease; physical activity; reliability; validity.

MeSH terms

  • Aged
  • Asthma*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Psychometrics
  • Pulmonary Disease, Chronic Obstructive* / diagnosis
  • Reproducibility of Results
  • Surveys and Questionnaires

Supplementary concepts

  • Pulmonary Disease, Chronic Obstructive, Severe Early-Onset

Grants and funding

This study was funded by AstraZeneca Farmacéutica Spain, S.A.